SCHEMBL1660428

SCHEMBL1660428

Oc1ccc(-c2ccn(-c3ccccc3)c2)cc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 6/20 0.55
COMT P21964 2/20 0.50
APP P05067 3/20 0.48
MIF P14174 2/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42
MAPT P10636 2/20 0.41
SNCA P37840 2/20 0.41
PTGS2 P35354 1/20 0.39
QDPR P09417 1/20 0.39
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17267004 0.81 COMT (0.48) COMTMEN1KMT2ARAB9AALDH1A1
SCHEMBL14007395 0.77 COMT (0.48) COMTMEN1KMT2ARAB9AALDH1A1
SCHEMBL7804885 0.75 COMT (0.53) COMTMEN1KMT2ARAB9AMAPT
SCHEMBL28092437 0.73 CYP1A2 (0.52) COMTMEN1GAAKMT2ARAB9A
SCHEMBL29848221 0.72 ALOX5 (1.00) ALOX5APPMEN1GAAKMT2A
SCHEMBL928289 0.72 ALOX5 (1.00) ALOX5APPMEN1GAAKMT2A
SCHEMBL182263 0.72 ADH5 (0.55) COMTRAB9A
SCHEMBL1660927 0.72 NPC1 (0.50) MEN1GAAKMT2ARAB9AMAPT
SCHEMBL2710486 0.72 KMO (0.59) COMTMEN1GAAKMT2ARAB9A
SCHEMBL17267006 0.72 COMT (0.56) COMTMEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307381-B1 NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2021-01-13 EP disclosed
EP-2687513-B1 DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2020-12-02 EP disclosed
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2019-10-08 US disclosed
EP-2684873-B1 DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2019-01-16 EP disclosed
US-20180346426-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2018-12-06 US disclosed
US-10071966-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN (DE) 2018-09-11 US disclosed
US-20160185730-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2016-06-30 US disclosed
CN-102056903-B New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases UNIV MUENCHEN L MAXIMILIANS 2015-04-15 CN disclosed
EP-2687513-A1 Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases Ludwig-Maximilians-Universität München (DE) 2014-01-22 EP disclosed
EP-2684873-A1 DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES Ludwig-Maximilians-Universität München (DE) 2014-01-15 EP disclosed
US-20110293520-A1 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. 2011-12-01 US disclosed
EP-2307381-A2 NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES Ludwig-Maximilians-Universität München (DE) 2011-04-13 EP disclosed
WO-2010000372-A2 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185730-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES PARK7, APP, HYPK ALOX5 4327/4885COMT 3799/4885APP 2/4885
US-10071966-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases PARK7, APP, HYPK ALOX5 4327/4885COMT 3799/4885APP 2/4885
US-20110293520-A1 NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES PARK7, HYPK, IK ALOX5 4547/4885COMT 3975/4885APP 6/4885
US-20180346426-A1 DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES PARK7, APP, HYPK ALOX5 4327/4885COMT 3799/4885APP 2/4885
US-10435373-B2 Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases PARK7, APP, HYPK ALOX5 4327/4885COMT 3799/4885APP 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.